PE firms back $77m round for Sophia Genetics

PE firms Idinvest Partners and Balderton Capital also took part, as well as Dutch pharmaceutical investment firm Alychlo.

The latest round brings total funding raised since inception to $140m and the fresh capital will be used to expand the global network of hospitals using Sophia’s technology, particularly in the US.

London-based Balderton is currently investing from its $375m sixth VC fund, which held a final close in November 2017.

Previous funding
Sophia raised seed funding of €653,000 from private investors in 2012 and a CHF 2.8m series-A a year later.

Invoke Capital, Swisscom and Endeavour Vision took part in a $13.75m series-B for the firm in 2014 before pharmaceutical investment firm Alychio led a $15m series-C.

Balderton joined the syndicate in 2017, leading a $30m series-D for the business alongside 360 Capital Partners and existing investors.

Company
Sophia was founded in Switzerland and is now co-based in Lausanne and Boston. The company’s technology is used to analyse genomic and radiomic data for diagnostic and treatment purposes. It is mainly used for oncology and hereditary disorders. The technology is currently used in 850 hospitals in 77 countries.

People
Balderton Capital – James Wise (partner).
Sophia Genetics – Jurgi Camblong (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Technology
• Healthcare
• Switzerland
• Venture
• Balderton Capital